KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Shares Outstanding (Diluted Average) (2017 - 2025)

Historic Shares Outstanding (Diluted Average) for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Q3 2025 value amounting to $56.6 million.

  • Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) rose 95.76% to $56.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.6 million, marking a year-over-year increase of 95.76%. This contributed to the annual value of $56.0 million for FY2024, which is 81.38% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) is $56.6 million, which was up 95.76% from $56.7 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $62.5 million during Q1 2023, with a 5-year trough of $54.2 million in Q1 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $57.3 million, with a median of $56.0 million in 2024.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) soared by 1347.22% in 2022, and later plummeted by 1093.21% in 2024.
  • Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $54.4 million in 2021, then rose by 13.47% to $61.7 million in 2022, then decreased by 10.01% to $55.5 million in 2023, then increased by 0.81% to $56.0 million in 2024, then grew by 1.06% to $56.6 million in 2025.
  • Its last three reported values are $56.6 million in Q3 2025, $56.7 million for Q2 2025, and $55.9 million during Q1 2025.